Advances in development, scale-up and manufacturing of microbicide gels, films, and tablets

Antiviral Research

Volumn 88, Issue SUPPL., 2010, Pages

  Garg, Sanjay ^a   Goldman, David ^b   Krumme, Markus ^c   Rohan, Lisa C ^d   Smoot, Stuart ^e   Friend, David R ^a,f  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b MedCrystalForms LLC   (United States)

^c LTS Lohmann Therapie Systeme AG   (United States)

^d UNIVERSITY OF PITTSBURGH   (United States)

^e USAF   (United States)

^f EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

Acceptability; Controlled release; Films; Gels; HIV; Microbicides; Regulations; Scale up; Tablets; Vaginal formulations

Indexed keywords

ANTIRETROVIRUS AGENT; CANDID V6; CANDIZOLE; CELLULOSE ACETATE; CELLULOSE ACETATE 1,2 BENZENEDICARBOXYLATE; CELLULOSE SULFATE; CLINDAMYCIN PHOSPHATE; CLOMAX; CLOTRIMAZOLE; DAPIVIRINE; DODECYL SULFATE SODIUM; DS 003; ITRACONAZOLE; MICONAZOLE; MICROBICIDE; N [4 CHLORO 3 (3 METHYL 2 BUTENYLOXY)PHENYL] 2 METHYL 3 FURANCARBOTHIOAMIDE; NEOMYCIN; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; NONOXINOL 9; POLYSTYRENESULFONIC ACID; POVIDONE IODINE; PRANEEM POLYHERBAL; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; TINIDAZOLE; UNCLASSIFIED DRUG;

CLINICAL TRIAL; CONTROLLED DRUG RELEASE; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG MANUFACTURE; DRUG PACKAGING; DRUG RESEARCH; DRUG SCREENING; FILM; GEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SCALE UP; TABLET; VAGINA; VAGINA CANDIDIASIS; VAGINA RING; VAGINITIS; VIRUS TRANSMISSION;

ADMINISTRATION, INTRAVAGINAL; ANTIVIRAL AGENTS; CHEMISTRY, PHARMACEUTICAL; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG AND NARCOTIC CONTROL; FEMALE; HIV; HIV INFECTIONS; HUMANS; PHARMACEUTICAL VEHICLES; RESEARCH DESIGN; TABLETS; VAGINA; VAGINAL CREAMS, FOAMS, AND JELLIES;

EID: 78649436881     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2010.09.010     Document Type: Review

References (57)

1. Anon., 2009a. Guidance for Industry, Q8(R2) Pharmaceutical Development. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm073507.pdf.
2. Anon., 2009b. Pharmaceutical cGMPS for the 21st Century - A Risk-Based Approach: Second Progress Report and Implementation Plan. http://www.fda.gov/drugs/developmentapprovalprocess/manufacturing/questionsandanswersoncurrentgoodmanufacturingpracticescgmpfordrugs/ucm071836.
3. Ahmad F.J., Alam M.A., Khan Z.I., Khar R.K., Ali M. Development and in vitro evaluation of an acid buffering bioadhesive vaginal gel for mixed infections. Acta Pharm. 2008, 58:407-419.
4. Baloĝlu E., Ozyazi{dotless}ci{dotless}a M., Ozyazici M., Hizarcioĝlu S.Y., Senyiĝit T., Ozyurt D., Pekçetin C. Bioadhesive controlled release systems of ornidazole for vaginal delivery. Pharm. Dev. Technol. 2006, 11:477-484.
5. British Pharmacopoeia, 2007.
6. Cone R.A. Barrier properties of mucus. Adv. Drug Deliv. Rev. 2009, 61:75-85.
7. Das Neves J., Bahia M.F. Gels as vaginal delivery systems. Int. J. Pharm. 2006, 318:1-14.
8. Dezzutti, C.S., 2008. Rectal Microbicides Update: Nonclinical Evaluation. Microbicides India. http://www.rectalmicrobicides.org/docs/Charlene%2520S.%2520Dezzutti.pdf.
9. Dobaria N., Mashru R. Design and in vitro evaluation of a novel bioadhesive vaginal drug delivery system for clindamycin phosphate. Pharm. Dev. Technol. 2010, 15:405-414.
10. Dobaria N.B., Badhan A.C., Mashru R.C. A novel itraconazole bioadhesive film for vaginal delivery: design, optimization, and physicodynamic characterization. AAPS PharmSciTech 2009, 10:951-959.
11. Doncel G., Clark M. Preclinical evaluation of anti-HIV microbicide products: new models and biomarkers. Antiviral Res. 2010, 88:S10-S18.
12. Du L.D., Jing-man N., Qing-gang M., Yan-bin S. Preparation of actinomycin D vaginal bioadhesive tablet. Chin. J. New Drugs 2007, 16:387-390.
13. El-Gindy G., El-Sayed A.M., Mohamed A.A. Mucoadhesive vaginal tablets of natamycin for vaginal candidiasis. Bull. Pharm. Sci. 2003, 26:29-40.
14. El-Kamel A., Sokar M., Naggar V., Gamal S. Bioadhesive controlled release metronidazole vaginal tablets. Acta Pharm. 2002, 52:171-179.
15. Elias C., Coggins C. Acceptability research on female-controlled barrier methods to prevent heterosexual transmission of HIV: where have we been? Where are we going?. J. Womens Health Gend. Based Med. 2001, 10:163-173.
16. Friend D.R., Doncel G.F. Combining prevention of HIV-1, other sexually transmitted infections and unintended pregnancies: development of dual-protection technologies. Antiviral Res. 2010, 88:S47-S54.
17. Fu Y., Yang S., Seong S.H., Kimura S., Park K. Orally fast disintegrating tablets: developments, technologies taste-masking and clinical studies. Crit. Rev. Ther. Drug Carrier Syst. 2004, 21:433-475.
18. Garg S., Vermani K., Garg A., Anderson R.A., Rencher W.B., Zaneveld L.J. Development and characterization of bioadhesive vaginal films of sodium polystyrene sulfonate (PSS), a novel contraceptive antimicrobial agent. Pharm. Res. 2005, 22:584-595.
19. Garg S., Vermani K., Kohli G., Kandarapu R., Tambwekar K., Garg A. Survey of vaginal formulations available in Indian market. Int. J. Pharm. Med. 2002, 16:141-152.
20. Genc L., Oguzlar C., Guler E. Studies on vaginal bioadhesive tablets of acyclovir. Pharmazie 2000, 55:297-299.
21. Goldman, D., 2005. US Patent Publication No.: US 2005/0181041 A1.
22. Gursoy A., Bayhan A. Testing of drug release from bioadhesive vaginal tablets. Drug Dev. Ind. Pharm. 1991, 17:2457-2475.
23. Ham A.S., Cost M.R., Sassi A.B., Dezzutti C.S., Rohan L.C. Targeted delivery of PSC-RANTES for HIV-1 prevention using biodegradable nanoparticles. Pharm. Res. 2009, 26:502-511.
24. Hariharan M., Bogue B.A. Orally dissolving film strips (ODFS): the final evolution of orally dissolving dosage forms. Drug Deliv. Technol. 2009, 9:24-29.
25. Hladik F., Doncel G.F. Preventing mucosal HIV transmission with topical microbicides - challenges and opportunities. Antiviral Res. 2010, 88:S3-S9.
26. Hoffman C. Comparative bioavailability of metronidazole formulations (Vagimid) after oral and vaginal administration. Int. J. Clin. Pharmacol. Ther. 1995, 33:232-239.
27. Joglekar N., Joshi S., Navlakha S., Katti U.R., Mehendale S.M. Acceptability of Praneem polyherbal vaginal tablet among HIV-unaffected women and their male partners in Pune India - phase I study. Indian J. Med. Res. 2006, 123:547-552.
28. Joshi S., Kati U., Godebole S. Phase I safety study of Praneem polyherbal vaginal tablet use among HIV-unaffected women and their male partners in Pune India. Trans. R. Soc. Trop. Med. Hyg. 2005, 99:769-774.
29. Kale V., Trivedi R., Muley P. Proposed design of a dissolution apparatus for vaginal formulations containing probiotics. Dissol. Technol. 2008, 15:27-29.
30. Klasse P., Shattock R., Moore J.P. Antiretroviral drug-based microbicides to prevent HIV-1 sexual transmission. Annu. Rev. Med. 2008, 59:455-471.
31. Kryger S., Moller N., Rassing M. Comments on the Ph. Eur. and the B. P. 80 disintegration test for suppositories and pessaries. Arch. Pharm. Chem. Sci. Ed. 1983, 11:79-84.
32. Lai B.E., Xie Q.Y., Lavine M.J., Szeri A.J., Owen D.H., Katz D.F. Dilution of microbicide gels with vaginal fluid and semen stimulants effect the rheological properties and coating properties. J. Pharm. Sci. 2008, 97:1030-1038.
33. Larsson B., Kjaeldgaard A. Combined vaginal and vulval treatment of vaginal candidiasis with econazole. Curr. Ther. Res. Clin. Exp. 1980, 27:664-669.
34. Lee C., Chien Y. Development and evaluation of mucoadhesive drug delivery system for dual controlled delivery of nonoxynol-9. J. Control. Release 1996, 39:93-103.
35. Malcolm R.K., Edwards K.L., Kiser P., Romano J., Smith T. Advances in microbicide vaginal rings. Antiviral Res. 2010, 88:S30-S39.
36. Mauck C.K., Baker J.M., Barr S.P., Johanson W.M., Archer D.F. A phase I comparative study of three contraceptive vaginal films containing nonoxynol-9. Postcoital testing and colposcopy. Contraception 1997, 56:97-102.
37. Mayer K.L., Maslanowski L.A., Gai F., El-Sadr W.M., Justman J., Kwiecien A., Mâsse B., Eshlemann S.H., Hendrix C., Morrow K., Rooney J.F., Soto-Torres I. Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active women. AIDS 2006, 20:543-551. the HPTN050 Protocolteam.
38. Morrow K., Hendrix C. Clinical evaluation of microbicide formulations. Antiviral Res. 2010, 88:S40-S46.
39. Ndesendo V.M., Pillay V., Choonara Y.E., Buchmann E., Bayever D.N., Meyer L.C. A review of current intravaginal drug delivery approaches employed for the prophylaxis of HIV/AIDS and prevention of sexually transmitted infections. AAPS PharmSciTech 2008, 9:505-520.
40. Neurath A.R., Strick N., Li Y.Y. Water dispersible microbicidal cellulose acetate phthalate film. BMC Infect. Dis. 2003, 3:27.
41. Modified-Release Drug Delivery Technology. Volume I Drug Delivery Technologies for the Oral Mucosal and Gastrointestinal Tract Routes 2008, Informa Healthcare, Inc., NY, USA. M.J. Rathbone, J. Hadgraft, M.S. Roberts, M. Lane (Eds.).
42. Raymond E., Alvarado G., Ledesma L., Diaz S., Bassol S., Morales E., Fernandez V., Carlos G. Acceptability of two spermicides in five countries. Contraception 1999, 60:45-50.
43. Raymond E.G., Chen P.L., Condon S., Luoto J., Barnhart K.T., Creinin M.D., Poindexter A., Wan L., Martens M., Schenken R., Blackwell R. Acceptability of five nonoxynol-9 spermicides. Contraception 2005, 71:438-442.
44. Roddy R.E., Zekeng L., Ryan K.A., Tamoufe U., Weir S.S., Wong E.L. A controlled trial of nonoxynol 9 film to reduce male-to-female transmission of sexually transmitted diseases. N. Engl. J. Med. 1998, 339:504-510.
45. Sassi A.B., Isaacs C.E., Moncla B.J., Gupta P., Hillier S.L., Rohan L.C. Effects of physiological fluids on physical-chemical characteristics and activity of topical vaginal microbicide products. J. Pharm. Sci. 2008, 97:3123-3139.
46. Schwartz J.L., Ballagh S.A., Kwok C., Mauck C.K., Weiner D.H., Rencher W.F., Callahan M.M. Fourteen-day safety and acceptability study of the universal placebo gel. Contraception 2007, 75:135-141.
47. Steiner M., Spruyt A., Joanis C., Glover L., Cordero M., Alvarado G., Onoka C. Acceptability of spermicidal film and foaming tablets among women in 3 countries. Int. Fam. Plan. Perspect. 1995, 21:104-107.
48. Szeri A.J., Park S.C., Verguet A., Weiss A., Katz D.F. A model of transluminal flow of an anti-HIV microbicide vehicle: combined elastic squeezing and gravitational sliding. Phys. Fluids 2008, 20:83-101.
49. Valenta C., Kast C., Harich I., Schnurch A.B. Development and in vitro evaluation of a mucoadhesive vaginal delivery system for progesterone. J. Control. Release 2001, 77:323-332.
50. Van Herrewege Y., Michiels J., Roey J.V., Fransen K., Kestins L., Balzarini J., Lewi P., Vanham G., Janssen P. In vitro evaluation of nonnucleoside reverse transcriptase inhibitors UC781 and TMC-120-RI 47681 as human immunodeficiency virus microbicides. Antimicrob. Agents Chemother. 2004, 48:337-339.
51. Wang L., Tang X. A novel ketoconazole bioadhesive tablet for vaginal delivery: design, in vitro and in vivo evaluation. Int. J. Pharm. 2008, 350:181-187.
52. Whaley K.J., Hanes J., Shattock R., Cone R.A., Friend D.R. Novel approaches to vaginal delivery and safety of microbicides: biopharmaceuticals, nanoparticles and vaccines. Antiviral Res. 2010, 88:S55-S66.
53. Wilkinson D., Ramjee G., Tholandi M., Rutherford G. Nonoxynol-9 for preventing vaginal acquisition of sexually transmitted infections by women from men. Cochrane Database Syst. Rev. 2002.
54. Woolfson A., Malcom R., Morrow R., Toner C., McCullagh S. Intravaginal ring delivery of the reverse transcriptase inhibitor TMC 120 as an HIV microbicide. Int. J. Pharm. 2006, 325:82-89.
55. Yamaguchi M., Tanno K. Design and evaluation of a new disintegration test apparatus for vaginal tablets. J. Pharm. Soc. Jpn. 1986, 106:228-232.
56. Yamaguchi M., Tanno K., Sugibayashi K., Morimoto Y. Disintegration test for vaginal tablets: comparison with BP test. J. Pharm. Pharmacol. 1990, 42:795-796.
57. Yoo J.W., Dharmala K., Lee C.H. The physicodynamic properties of mucoadhesive polymeric films developed as female controlled drug delivery system. Int. J. Pharm. 2006, 309:139-145.